Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $107.00.

Several analysts have recently issued reports on the company. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Morgan Stanley assumed coverage on shares of Monopar Therapeutics in a research report on Friday, January 9th. They issued an “overweight” rating and a $115.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a research note on Thursday, January 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $54.10 on Wednesday. The stock has a market capitalization of $361.55 million, a price-to-earnings ratio of -29.73 and a beta of 1.58. Monopar Therapeutics has a 12-month low of $26.06 and a 12-month high of $105.00. The stock’s 50-day moving average price is $59.62 and its 200-day moving average price is $70.95.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). As a group, research analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MNPR. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics during the third quarter worth approximately $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the second quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Monopar Therapeutics in the 4th quarter worth approximately $65,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.